Response to PD1 inhibition in conventional chondrosarcoma
Abstract Background Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy. Case presentation We describe a 67-year-old man with metastatic conventional...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2018-09-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40425-018-0413-z |
| _version_ | 1819162995656228864 |
|---|---|
| author | Michael J. Wagner Robert W. Ricciotti Jose Mantilla Elizabeth T. Loggers Seth M. Pollack Lee D. Cranmer |
| author_facet | Michael J. Wagner Robert W. Ricciotti Jose Mantilla Elizabeth T. Loggers Seth M. Pollack Lee D. Cranmer |
| author_sort | Michael J. Wagner |
| collection | DOAJ |
| description | Abstract Background Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy. Case presentation We describe a 67-year-old man with metastatic conventional chondrosarcoma who was treated with nivolumab. Treatment was discontinued after restaging showed increased tumor burden, which later proved to be pseudoprogression. The patient restarted nivolumab and continues to have a near complete response. Conclusion Conventional chondrosarcoma may be sensitive to checkpoint inhibitors. Further, this case demonstrates clearly the phenomenon of pseudo-progression in this disease, a factor that must be considered in the design of clinical trials and clinical care. This case supports additional study of immunomodulatory agents in this deadly disease. |
| first_indexed | 2024-12-22T17:37:06Z |
| format | Article |
| id | doaj.art-d2985005c8ee4377ac381eafa38dbf81 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-22T17:37:06Z |
| publishDate | 2018-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-d2985005c8ee4377ac381eafa38dbf812022-12-21T18:18:30ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262018-09-01611410.1186/s40425-018-0413-zResponse to PD1 inhibition in conventional chondrosarcomaMichael J. Wagner0Robert W. Ricciotti1Jose Mantilla2Elizabeth T. Loggers3Seth M. Pollack4Lee D. Cranmer5Division of Medical Oncology, University of Washington School of MedicineDepartment of Pathology, University of Washington School of MedicineDepartment of Pathology, University of Washington School of MedicineDivision of Medical Oncology, University of Washington School of MedicineDivision of Medical Oncology, University of Washington School of MedicineDivision of Medical Oncology, University of Washington School of MedicineAbstract Background Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy. Case presentation We describe a 67-year-old man with metastatic conventional chondrosarcoma who was treated with nivolumab. Treatment was discontinued after restaging showed increased tumor burden, which later proved to be pseudoprogression. The patient restarted nivolumab and continues to have a near complete response. Conclusion Conventional chondrosarcoma may be sensitive to checkpoint inhibitors. Further, this case demonstrates clearly the phenomenon of pseudo-progression in this disease, a factor that must be considered in the design of clinical trials and clinical care. This case supports additional study of immunomodulatory agents in this deadly disease.http://link.springer.com/article/10.1186/s40425-018-0413-zChondrosarcomaImmunotherapySarcomaBone cancer |
| spellingShingle | Michael J. Wagner Robert W. Ricciotti Jose Mantilla Elizabeth T. Loggers Seth M. Pollack Lee D. Cranmer Response to PD1 inhibition in conventional chondrosarcoma Journal for ImmunoTherapy of Cancer Chondrosarcoma Immunotherapy Sarcoma Bone cancer |
| title | Response to PD1 inhibition in conventional chondrosarcoma |
| title_full | Response to PD1 inhibition in conventional chondrosarcoma |
| title_fullStr | Response to PD1 inhibition in conventional chondrosarcoma |
| title_full_unstemmed | Response to PD1 inhibition in conventional chondrosarcoma |
| title_short | Response to PD1 inhibition in conventional chondrosarcoma |
| title_sort | response to pd1 inhibition in conventional chondrosarcoma |
| topic | Chondrosarcoma Immunotherapy Sarcoma Bone cancer |
| url | http://link.springer.com/article/10.1186/s40425-018-0413-z |
| work_keys_str_mv | AT michaeljwagner responsetopd1inhibitioninconventionalchondrosarcoma AT robertwricciotti responsetopd1inhibitioninconventionalchondrosarcoma AT josemantilla responsetopd1inhibitioninconventionalchondrosarcoma AT elizabethtloggers responsetopd1inhibitioninconventionalchondrosarcoma AT sethmpollack responsetopd1inhibitioninconventionalchondrosarcoma AT leedcranmer responsetopd1inhibitioninconventionalchondrosarcoma |